0001493152-26-015413
SEC filingGT Biopharma entered into an Investigator Initiated Clinical Trial Agreement with the University of Minnesota for a phase 1a/1b trial of GTB-5550 in advanced solid tumors, with Company funding up to $3.8 million over three years.
GT Biopharma has formalized an Investigator Initiated Clinical Trial Agreement with the University of Minnesota, enabling the launch of a phase 1a/1b study for GTB-5550, a camelid nanobody B7-H3 tri-specific killer engager targeting advanced solid tumors post prior therapy failure. The University, through Sponsor-Investigator Nicholas Zorko, MD, will handle IND sponsorship (IND 169118) and trial execution, while the Company funds up to $3.8 million over three years and supplies the drug free of charge. This arrangement advances GTBP's TriKE platform in oncology without direct commercialization intent by the University, building on their prior exclusive license agreement. Termination flexibility with 30-day notice or immediate action for safety/breach provides risk management, and mutual publication rights ensure data transparency for investors tracking clinical progress.